Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
7,341 total articles
Travere Therapeutics' Chief Legal Officer, Elizabeth E. Reed, sold 46,600 shares of common stock on April 14 and 15, 2026, realizing roughly $2.13 million. The transactions followed option exercises and the vesting of performance restricted stock units tied to FDA approval of the company's drug Filspari. The equity trades occurred as the shares tra…
Travere Therapeutics Chief Financial Officer Christopher R. Cline reported a series of stock transactions between April 13 and April 15, 2026, that resulted in $348,974 of sales. The filings show discrete sales at prices ranging from $28.85 to $42.61, and the same filings show a separate award of 14,000 common shares at $0 following the vesting of …
Travere Therapeutics CEO Eric M. Dube sold 63,900 shares of common stock on April 15, 2026, in transactions totaling about $2.63 million. The disposals, carried out under a 10b5-1 plan adopted June 16, 2025, coincided with the stock trading near its 52-week high after a 181% gain over the past year. The sales covered tax obligations tied to newly v…
Travere Therapeutics Inc (NASDAQ:TVTX) Chief Commercial Officer Heerma Peter reported a sale of 7,215 shares on April 14, 2026, generating $302,516. The disposition followed a vesting of 14,000 performance-restricted stock units tied to FDA approval of Filspari, with the executive now holding 138,608 shares. The company’s stock is trading near a 52…
Travere Therapeutics Chief Medical Officer Jula Inrig sold 8,233 shares of common stock across April 14 and April 15, 2026, realizing roughly $345,893. The transactions followed the vesting of performance restricted stock units that delivered 14,000 shares on April 13. The insider sales, some executed to meet tax liabilities and including a pre-arr…
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman sold 20,406 shares on April 13 and April 15, 2026, for roughly $548,672 under a pre-arranged Rule 10b5-1 plan. Rodman also exercised options for 14,058 shares on April 13 and now holds 69,792 shares directly. The company reported fourth-quarter 2025 earnings with an EPS of -0.4, beati…
Mineralys Therapeutics Chief Executive Officer Jon Congleton sold 15,730 shares on April 13, 2026, generating roughly $421,979 at weighted-average prices between $26.81 and $26.96. The transaction was carried out under a Rule 10b5-1 plan adopted December 30, 2025. Congleton still holds 689,321 shares. The company reported Q4 2025 EPS of -0.4 versus…
Electronic Arts Chief People Officer Vijayanthimala Singh, through the Singh-Force Family Trust, sold 1,200 shares on April 15, 2026 at $203.25 each, totaling $243,900. The transaction occurred while EA shares traded close to a 52-week high and amid advancing merger steps and upbeat fiscal third-quarter results. The trust retains 28,760 shares foll…
Electronic Arts CEO Andrew Wilson sold 5,000 shares on April 15, 2026 under a previously arranged 10b5-1 plan, generating $1016058 in proceeds. The trade occurred while EA shares were trading close to a 52-week peak, amid strong quarterly results and progress on a proposed buyout by an investor consortium.
Ouster Chief Technology Officer Mark Frichtl sold 60,000 shares of common stock across April 14 and 15, 2026, for about $1.39 million, according to a Form 4 filing. The transactions were carried out under a pre-arranged Rule 10b5-1 plan and coincided with robust stock performance and solid fourth-quarter results reported by the company.
Laura Miele, President of EA Entertainment at Electronic Arts Inc. (NASDAQ: EA), sold 2,500 shares on April 15, 2026, for $508,025 under a previously established 10b5-1 plan. The transaction occurred as EA shares hovered close to their 52-week high, and follows strong fiscal third-quarter results and progress on a proposed merger with an investor c…
Annabelle G. Bexiga, a member of StoneX Group Inc.'s board, sold 1,500 shares of the company's common stock on April 15, 2026, for $152,865. The transaction occurred as the stock traded close to its 52-week high. The company has also announced several strategic moves to bolster cross-border payments, launched a securitization and capital markets pl…
Alignment Healthcare President Dawn Christine Maroney sold 30,000 shares on April 15, 2026, generating roughly $626,199 in proceeds. The sale was executed at prices between $20.76 and $21.07 per share. Maroney retains direct ownership of 1,028,813 shares. The transaction comes while the stock sits about 80% above its 52-week low and is noted by Inv…
Infinite Acquisitions Partners LLC disposed of 3,950,000 Class A shares of Falcon’s Beyond Global, Inc. (FBYD) on April 14, 2026, at $13.40 per share for a total of $52,830,000. The Form 4 filing also records delivery of 2,000,000 shares to satisfy redemption obligations and a 100,000-share distribution to Infinite Acquisitions shareholders. After …
Somalya Saema, Remitly Global's Chief Legal, Compliance, and Administrative Officer, sold 35,976 shares of Remitly common stock across two trades on April 14-15, 2026, generating $650,184. The sales were made under a Rule 10b5-1 plan adopted March 12, 2025. Remitly reported stronger-than-expected fourth-quarter results and issued guidance for the f…
Remitly Global director Joshua Hug sold 23,000 shares of common stock in transactions on April 14 and 15, 2026, generating about $434,695. The trades were carried out under a previously adopted Rule 10b5-1 plan. The stock has risen 37% year-to-date and the company reported fourth-quarter revenue and adjusted EBITDA above Street estimates, alongside…
Jonathan M. Craig, MD, Head of Retail Investing at Charles Schwab (SCHW), sold 21,750 shares on April 14, 2026, for $2,153,326 at a weighted average price of $99.0035. On the same day he exercised nonqualified options for 21,750 shares at $46.81 each, contributing the shares to a revocable trust. The sales were executed under a Rule 10b5-1 plan ado…
Matthew Paul Larson, Chief Risk Officer at Slide Insurance Holdings, sold 10,000 shares on April 13, 2026, raising about $180,000, and exercised 10,000 options the same day. The moves were made under a 10b5-1 plan. Slide reported robust fourth-quarter 2025 results and has completed one repurchase program while authorizing another.
Bryan Ball, Chief Technical Operations Officer and Senior Vice President of Manufacturing Operations at Whitehawk Therapeutics, executed two broker-assisted stock sales on April 13 and 14, 2026, disposing of 118,849 shares for a total of $427,860. The transactions were conducted to cover tax liabilities from the vesting of restricted stock units an…
Nigel J. Murtagh, Chief Risk Officer at Charles Schwab, sold 41,297 shares of SCHW on April 14, 2026 for about $4.08 million and exercised options to acquire the same number of shares at a $52.05 strike. The transactions were conducted under a pre-arranged Rule 10b5-1 plan and leave Murtagh with roughly 57,972.4846 directly held shares plus 2,484 s…
Airwa Inc. director Zhou Hongyu purchased 10,000 shares on April 10, 2026, for $9,100 as the stock trades near a 52-week low. The company completed a $140 million acquisition of Aberfeldy Holdings Limited and entered a private securities purchase agreement involving 4.2 million shares with its chairman. Financial metrics and valuation signals cited…
Photronics Inc. director Lee Kang Jyh sold 5,000 shares of common stock on April 13, 2026, at $45 per share for $225,000 and simultaneously exercised 5,000 options with an $8.6 strike, costing $43,000. The trade comes as PLAB trades close to a 52-week high following strong one-year returns. Photronics also posted fiscal Q1 2026 results that beat an…
Genprex director Brent M Longnecker executed two transactions on April 14, 2026, disposing of 18 shares of common stock at $1.23 per share for an aggregate of about $22. The sale was reported on a Form 4 and included both direct and indirect sales. Separately, Genprex announced upcoming preclinical presentations on its REQORSA gene therapy and has …
Arista Networks CEO and chairperson Jayshree Ullal executed a block sale of company shares on April 13, 2026, disposing of 112,812 shares for $16,934,671 under a pre-set Rule 10b5-1 trading plan. The transactions left Ullal with a small direct holding while multiple trusts controlled substantial indirect positions. The sale occurred as the stock tr…
Oruka Therapeutics' Chief Medical Officer, Joana Goncalves, sold 7,000 shares on April 15, 2026, for about $462,829 under a Rule 10b5-1 plan she set last September, while simultaneously exercising options to acquire 7,000 shares. The stock is trading near its 52-week high after a steep 666% annual gain and draws mixed signals - heavy analyst optimi…
